PolyPid (PolyPid) ROCE % : -183.74% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is PolyPid ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PolyPid's annualized ROCE % for the quarter that ended in Dec. 2023 was -183.74%.

PolyPid ROCE % Historical Data

The historical data trend for PolyPid's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPid ROCE % Chart

PolyPid Annual Data

Trend

Dec12

Dec13

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-88.45

-70.80

-78.07

-143.36

-173.92

PolyPid Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-122.84	-111.26	-103.44	-117.39	-183.74

PolyPid ROCE % Calculation

PolyPid's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-22.178	/	( ( (25.971 - 8.553)	+	(15.372 - 7.286) )	/ 2 )
	=	-22.178	/	( (17.418	+	8.086)	/ 2 )
	=	-22.178	/	12.752
	=	-173.92 %

PolyPid's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-21.24	/	( ( (20.932 - 5.898)	+	(15.372 - 7.286) )	/ 2 )
	=	-21.24	/	( ( 15.034	+	8.086 )	/ 2 )
	=	-21.24	/	11.56
	=	-183.74 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

PolyPid (NAS:PYPD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PolyPid ROCE % Related Terms

Thank you for viewing the detailed overview of PolyPid's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PolyPid (PolyPid) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PolyPid Ltd (NAS:PYPD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Hasivim Street, P.O Box 7126, Petach Tikva, ISR, 495376

Website

https://www.polypid.com

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, and Bacyssio are trademarks of the company. The company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.